DENN domain containing 1BGenealiases: C1ORF18 · C1orf218 · FAM31B
Q-omics provides the consensus-scored DENND1B profile across patient tissues and cancer cell-line models. DENND1B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DENND1B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, DENND1B RNA expression shows 20,285 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where DENND1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DENND1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DENND1B survival associations across molecular data types. DENND1B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DENND1B RNA expression–survival associations across cancer types. High DENND1B expression shows favorable associations in HNSC, LUAD, SKCM, BRCA, COAD and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DENND1B RNA expression.
This table summarizes DENND1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DENND1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DENND1B shows lower tumor expression in KIRC, COAD and THCA and higher tumor expression in HNSC, BLCA and BRCA. The KIRC box plot shows higher DENND1B RNA expression in normal versus tumor tissue (log2 FC = −0.822, t-test p < 0.001).
This table shows molecular features associated with DENND1B in patient tissues and cancer cell lines. In patient samples, DENND1B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DENND1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
